Results 21 to 30 of about 412 (129)
Clinical outcomes of pars plana vitrectomy with endoresection in uveal melanoma primarily treated with plaque radiotherapy or proton beam therapy [PDF]
European Journal of OphthalmologyThomas J van Rijssen +2 more
exaly +2 more sources
Endoresection of choroidal melanoma: practical and safety considerations. [PDF]
Eye (Lond)Anguita R, Kiilgaard JF.
europepmc +2 more sources
Respond to: Safe endoresection
Indian Journal of Ophthalmology, 2015 Mehdi Modarres +2 more
doaj +2 more sources
Local Resection in Choroidal Melanoma: A Review. [PDF]
J Clin Med, 2022 Surgical resection is widely used to treat small tumours located in the iris and the ciliary body, due to the accessibility of these sites. By contrast, surgical removal of choroidal tumours is substantially more challenging, which is why this procedure ...
Caminal JM +9 more
europepmc +2 more sources
Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma. [PDF]
Cancer Rep (Hoboken)ABSTRACT Background Uveal melanoma (UM) is the prevailing malignant tumor that develops within the eye in adults, and it has a bleak outlook because of the few treatment choices available and the high likelihood of returning after treatment. Currently, surgical intervention, radiation therapy, and a combination of both modalities are available ...
Azani A +13 more
europepmc +2 more sources
Current management of uveal melanoma: A review
Clinical &Experimental Ophthalmology, Volume 51, Issue 5, Page 484-494, July 2023., 2023 Abstract Uveal melanoma is the most frequent primary intraocular cancer in adulthood and is mostly localised to the choroid. It can be treated using radiation therapy, laser therapy, local resection and enucleation, with the best results achieved by combining these procedures. However, up to half of patients develop metastatic disease.
Haixia Bai +2 more
wiley +1 more source
Fractionated stereotactic radiotherapy for uveal melanoma: Long‐term outcome and control rates
Acta Ophthalmologica, Volume 100, Issue 5, Page 511-519, August 2022., 2022 Abstract Purpose The aim of our study is to evaluate local tumour control rates, radiation side‐effects, visual preservation and disease‐free survival (DFS) of uveal melanoma (UM) patients treated with fractionated stereotactic radiotherapy (fSRT). Methods A retrospective study of UM patients, who were treated with fSRT (N = 189), was performed by the ...
Jackelien G. M. van Beek +7 more
wiley +1 more source
The Journal of Pathology: Clinical Research, Volume 8, Issue 4, Page 383-394, July 2022., 2022 Abstract Uveal melanoma (UM) is the most common intraocular cancer in adults. Whilst treatment of primary UM (PUM) is often successful, around 50% of patients develop metastatic disease with poor outcomes, linked to chromosome 3 loss (monosomy 3, M3). Advances in understanding UM cell biology may indicate new therapeutic options.
Dorota Sabat‐Pośpiech +6 more
wiley +1 more source
Acta Ophthalmologica, Volume 100, Issue 1, Page e38-e46, February 2022., 2022 Abstract Importance Approximately twenty per cent of Von Hippel–Lindau patients with retinal haemangioblastomas (RH) suffer from visual impairment. Various treatment options are available for peripheral RH. However, management of peripheral RH is complex due to multifocality and bilaterality.
Anass Hajjaj +4 more
wiley +1 more source
Cancer Medicine, Volume 10, Issue 17, Page 5974-5982, September 2021., 2021 In metastasized uveal melanoma (UM) patients, circulating tumor DNA (ctDNA) can be detected in blood. Here we explored if cfDNA is a suitable biomarker for the early detection of metastatic disease in UM patients. Our data show that this biomarker fulfills the expectation as, overall, about half of the patients who developed metastases showed a ...
Claudia H. D. Le Guin +6 more
wiley +1 more source